<DOC>
	<DOCNO>NCT01712334</DOCNO>
	<brief_summary>This phase IV , multicenter , randomize , open-label , two-period crossover study evaluate comparable efficacy safety Pulmozyme ( dornase alfa ) deliver eRapid nebulizer system patient cystic fibrosis . Patients receive Pulmozyme daily chronically least 6 month continue receive Pulmozyme daily run-in period 2 week use Pari LC Plus nebulizer . Patients randomize receive crossover design Pulmozyme daily two treatment period 2 week use either Pari LC Plus eRapid nebulizer . Anticipated time study treatment 6 week .</brief_summary>
	<brief_title>A Study Comparable Efficacy Safety Pulmozyme ( Dornase Alfa ) Delivered eRapid Nebulizer System Patients With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Male female patient , &gt; /= 6 year age Confirmed diagnosis cystic fibrosis ( CF ) Receiving Pulmozyme daily chronically treatment CF least 6 month prior screen Percent predict FEV1 &gt; /= 40 % screen base Wang ( male &lt; 18 year , females &lt; 16 year ) Hankinson ( male &gt; /= 18 year , female &gt; /= 16 year ) standardize equation Able reproducibly perform spirometry test comply study assessments An acute respiratory infection pulmonary exacerbation within 4 week prior randomization Initiation new chronic therapy ( e.g . inhaled corticosteroid , inhaled oral antibiotic , highdose ibuprofen , hypertonic saline , ivacaftor ) respiratory disease within 4 week prior randomization Changes chest physiotherapy schedule within 4 week prior randomization Hospitalization within 4 week prior randomization Planned hospitalization 6week study History organ transplantation Participation investigational drug device study within 30 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>